{"product_id":"vtak-bcg-matrix","title":"(VTAK) Catheter Precision, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Catheter Precision, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVIVO flagship system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVIVO is Catheter Precision, Inc.’s core branded platform and its most differentiated asset, because it supports non-invasive 3D cardiac mapping. In BCG terms, it fits the Stars bucket: the clearest high-growth bet and the strongest candidate to become a long-term category leader. Its value is strategic, not just clinical, because it gives Catheter Precision a sharper market position than a single-device play.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIdiopathic ventricular arrhythmia mapping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIdiopathic ventricular arrhythmia mapping is a focused EP use case, not a broad tool, and that specialization can support adoption as physician confidence rises. Idiopathic ventricular arrhythmias make up about 10% to 20% of ventricular arrhythmia cases, so the niche is real but limited. Its high clinical specificity gives Catheter Precision, Inc. more value per case than a generic mapping tool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-invasive 3D cardiac mapping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNon-invasive 3D cardiac mapping is Catheter Precision, Inc.'s core VIVO technology, and it targets a hard EP workflow with a simpler, non-invasive path. As placements grow, it can lift the product mix toward a higher-value recurring platform. That makes it the clearest Stars asset in the BCG view.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePre-procedure localization workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCatheter Precision, Inc.'s pre-procedure localization workflow is used before an electrophysiology procedure, so it supports planning and can cut uncertainty without replacing the core case. That matters in a market where labs value faster setup, cleaner targeting, and fewer workflow misses. As adoption expands, this kind of efficiency tool fits a Star profile if use keeps scaling.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePre-procedure, not procedure replacement\u003c\/li\u003e\n\u003cli\u003eImproves planning and workflow speed\u003c\/li\u003e\n\u003cli\u003eReduces localization uncertainty\u003c\/li\u003e\n\u003cli\u003eStar fit depends on rising adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. EP physician adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eU.S. EP physician adoption is the key Stars driver for Catheter Precision, because the Company sells into U.S. hospitals and labs, and a small medtech can grow fast only if physicians keep using VIVO and expand use across cases. In this setup, each new EP doctor matters more than broad brand awareness, since repeat use can turn one hospital into a scalable revenue base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhysician buy-in drives repeat VIVO use.\u003c\/li\u003e\n\u003cli\u003eHospital rollout can follow clinical trust.\u003c\/li\u003e\n\u003cli\u003eMore adopters can lift U.S. market share.\u003c\/li\u003e\n\u003cli\u003eScaling depends on EP conversion speed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVIVO: Catheter Precision’s Growth Engine in 3D Cardiac Mapping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVIVO is Catheter Precision, Inc.’s Star asset: non-invasive 3D cardiac mapping with the clearest growth upside. Idiopathic ventricular arrhythmias are about 10% to 20% of ventricular arrhythmia cases, so the niche is real, but focused. As EP physician adoption rises, repeat use can turn each hospital into a higher-value base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar driver\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget use\u003c\/td\u003e\n\u003ctd\u003eIdiopathic ventricular arrhythmia mapping\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003ctd\u003eAbout 10% to 20% of VA cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue lever\u003c\/td\u003e\n\u003ctd\u003eNon-invasive 3D pre-procedure planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStar signal\u003c\/td\u003e\n\u003ctd\u003eAdoption-led repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCatheter Precision BCG Matrix maps products into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClean, one-page BCG Matrix for Catheter Precision, Inc. that quickly spots pain points and growth priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail that boosts confidence in Catheter Precision, Inc. claims and speeds up due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmigo Remote Catheter System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmigo Remote Catheter System is one of Catheter Precision, Inc.'s established product lines, so it fits the cash cow profile more than the newer VIVO opportunity. Its value comes from installed-base demand and repeat use, which can support steadier revenue if hospitals keep using the system. Mature products like this often trade growth for predictability, which is why Amigo can be a stable cash generator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLockeT suture retention device\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLockeT is a narrower, simpler product than VIVO, so it fits the kind of lower-growth accessory line that can quietly generate cash from existing hospital accounts. If Catheter Precision keeps LockeT attached to its installed base, it can support repeat sales with lower selling effort and less development spend. That makes LockeT a plausible BCG cash cow, even though Catheter Precision has not broken out LockeT-only revenue in recent public filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstalled-base support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInstalled-base support can bring Catheter Precision, Inc. recurring service revenue without heavy new-sales spend, which fits a cash-cow pattern. In its 2025 filings, the company remained a small medtech player, so each supported system matters more for margin than for growth. This kind of support work is steadier than product launches and can help offset the lower-growth profile of an existing installed base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eService and maintenance revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCatheter Precision, Inc. can treat service and maintenance revenue as a Cash Cow because it is steadier than new product launches and usually needs less selling spend. In 2025, this kind of recurring revenue is valuable for funding R\u0026amp;D and commercialization while keeping cash flow more predictable.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring, lower-touch revenue\u003c\/li\u003e\n\u003cli\u003eLess marketing than growth products\u003c\/li\u003e\n\u003cli\u003eSupports R\u0026amp;D funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExisting hospital accounts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExisting hospital accounts are a real cash cow for Catheter Precision, Inc. because repeat orders from installed sites can keep revenue flowing without the heavy selling spend that new electrophysiology accounts demand. In a small-product portfolio, stable hospital relationships matter more, since a single active account can keep VIVO and other tools moving with lower churn risk and better margin support.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat buys cut acquisition costs.\u003c\/li\u003e\n\u003cli\u003eEP sales cycles are long and costly.\u003c\/li\u003e\n\u003cli\u003eInstalled sites can fund growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCatheter Precision’s Cash Cows Keep the Money Flowing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCatheter Precision, Inc. Cash Cows are its installed-base products and support revenue, led by Amigo and LockeT, which can keep cash coming in after launch spend is already sunk. In 2025 filings, the company still depended on repeat hospital use and service work more than on new-product growth, so these lines fit a low-growth, cash-generating profile. That matters because steady reorders and support fees can help fund R\u0026amp;D and sales for VIVO.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow driver\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmigo\u003c\/td\u003e\n\u003ctd\u003eInstalled-base repeat use\u003c\/td\u003e\n\u003ctd\u003eNo segment revenue split\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLockeT\u003c\/td\u003e\n\u003ctd\u003eLow-touch repeat sales\u003c\/td\u003e\n\u003ctd\u003eNo product-only disclosure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService\u003c\/td\u003e\n\u003ctd\u003eRecurring support income\u003c\/td\u003e\n\u003ctd\u003eReported in filings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eCatheter Precision, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Catheter Precision, Inc. BCG Matrix preview you’re viewing is the exact document you’ll receive after purchase. No mockups, no watermarks, and no demo content—just the complete, ready-to-use report. Once purchased, you’ll get the same formatted file instantly for download. It’s designed for clear strategic analysis and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFormer Ra Medical legacy assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFormer Ra Medical legacy assets fit the \"Dog\" slot because Catheter Precision, Inc. changed its name from Ra Medical Systems in August 2023 and now centers on EP-only products. That leaves older assets with weak strategic fit, low growth, and limited share appeal. In FY2025, the company still reported a small revenue base, so legacy items likely add little to the current growth story.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-EP product history\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCatheter Precision’s current story is almost entirely electrophysiology, led by VIVO and LockeT, so older non-EP product lines have little strategic fit. That legacy mix can still soak up management time, but it is unlikely to move the growth needle versus the 2-product EP core. In BCG terms, these non-EP dogs are weak candidates for reinvestment unless they can be exited or repurposed fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-volume peripheral line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCatheter Precision, Inc.’s low-volume peripheral line fits the dog profile: it sits outside the core electrophysiology focus, so it is harder to scale and less likely to build meaningful share. When sales stay small, the product tends to absorb effort without adding enough growth or margin to matter. That makes it a weak fit for a BCG Matrix portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUnderused commercial channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCatheter Precision, Inc. has only a small revenue base, so low-throughput channels can drain scarce selling time fast. If a channel does not feed core products like LockeT or Amigo and cannot scale, it fits BCG Dogs: weak growth, weak return, and a high chance of wasting effort.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall channels can absorb sales effort.\u003c\/li\u003e\n\u003cli\u003eLow throughput limits payback.\u003c\/li\u003e\n\u003cli\u003eKeep only core-product feeders.\u003c\/li\u003e\n\u003cli\u003eDrop channels that do not scale.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStalled commercialization efforts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCatheter Precision, Inc.’s stalled commercialization efforts fit the Dogs box when programs fail to turn pilot use into placements or repeat orders. These drains can keep absorbing cash, sales time, and distributor focus, while the latest filings still show a small revenue base and no clear proof of scalable demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeak placement conversion\u003c\/li\u003e\n\u003cli\u003eNo repeat-order momentum\u003c\/li\u003e\n\u003cli\u003eCash and time drain\u003c\/li\u003e\n\u003cli\u003eBest cut or exit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCatheter Precision’s Legacy Dogs: Low-Value Assets in an EP-Only Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCatheter Precision, Inc.’s Dogs are the legacy Ra Medical and other non-EP assets: they no longer match the company’s EP-only push after the August 2023 name change, and they sit in a low-growth, low-share bucket. FY2025 still showed a small revenue base, so these lines likely add little value while using cash and sales time. Best case is exit or repurpose, not reinvestment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog asset group\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy non-EP assets\u003c\/td\u003e\n\u003ctd\u003eWeak strategic fit\u003c\/td\u003e\n\u003ctd\u003eSmall revenue base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLow-volume channels\u003c\/td\u003e\n\u003ctd\u003eLow growth, low share\u003c\/td\u003e\n\u003ctd\u003eLimited scale-up proof\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVIVO broader indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVIVO fits the question mark bucket: it is strong in its current electrophysiology niche, but broader use is still unproven. New indications could lift revenue, yet each one would likely need fresh clinical evidence, regulatory work, and sales spend before adoption scales. That is why the upside is real, but the cash burn risk is too, until Catheter Precision, Inc. shows repeatable demand beyond the core use case.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational VIVO launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCatheter Precision remains U.S.-centric, so International VIVO launch is still a Question Mark. International sales can expand the base, but new-country entry adds regulatory steps, local distributor costs, and slower reimbursement timelines, so share gains are uncertain until adoption builds. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmigo growth reset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmigo is an established Catheter Precision system, but its growth path is still unclear, so it fits Question Marks in the BCG Matrix. If Catheter Precision reinvests in sales, education, and repositioning, Amigo could gain stronger market pull. Without that push, its future stays uncertain and its share of growth remains weak.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNext-gen EP robotics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRobotic catheter control is still a real growth lane in electrophysiology, but Catheter Precision, Inc. has not shown the share gain needed to move next-gen EP robotics from a question mark to a star. The global electrophysiology device market is roughly in the low-double-digit billions of dollars, so the prize is big, but Catheter Precision, Inc. remains a speculative bet until it proves adoption. One line: growth is there, but proof is not.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket is growing fast.\u003c\/li\u003e\n\u003cli\u003eCatheter Precision, Inc. lacks share proof.\u003c\/li\u003e\n\u003cli\u003eStill a speculative bet.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew distribution partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNew distribution partnerships can speed Catheter Precision, Inc.’s sales reach faster than building a bigger direct team, but they stay a question mark until channel margins and sell-through prove they work. If distributor commissions, rebates, or stocking terms eat too much margin, the deal can add revenue but not profit. That is why these partnerships are promising, but still unproven.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster reach, lower upfront selling cost\u003c\/li\u003e\n\u003cli\u003eMargin risk can kill the channel\u003c\/li\u003e\n\u003cli\u003eStill unproven, so it stays a Question Mark\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCatheter Precision’s Biggest Bets Still Need Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCatheter Precision, Inc. question marks are the growth bets with the least proof: VIVO expansion, Amigo, international sales, robotics, and new channels. They can lift revenue, but FY2025 still showed limited scale and no clear share win, so each needs more clinical, regulatory, and sales proof before it can move out of Question Mark status.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eQuestion mark\u003c\/th\u003e\n\u003cth\u003eFY2025 proof\u003c\/th\u003e\n\u003cth\u003eKey risk\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVIVO\u003c\/td\u003e\n\u003ctd\u003eEarly adoption\u003c\/td\u003e\n\u003ctd\u003eNeeds new evidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational launch\u003c\/td\u003e\n\u003ctd\u003eLimited base\u003c\/td\u003e\n\u003ctd\u003eRegulatory delay\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmigo\u003c\/td\u003e\n\u003ctd\u003eUnclear growth\u003c\/td\u003e\n\u003ctd\u003eWeak pull\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRobotics\u003c\/td\u003e\n\u003ctd\u003eNo share proof\u003c\/td\u003e\n\u003ctd\u003eHigh cash burn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235186483465,"sku":"vtak-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vtak-bcg-matrix.webp?v=1785735669","url":"https:\/\/dcfanalyst.com\/products\/vtak-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}